

Application Serial No.: 10/606,055
Amendment dated: March 30, 2006
Response to Office Action dated January 3, 2006

2

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. - 24. (Canceled)

25. (Currently amended) A method of reducing kidney fibrosis in a mammal comprising administering to a mammal having a fibroproliferative disorder of kidney a composition comprising an antibody that specifically binds to an epitope of a protein as shown in SEQ ID NO:2 from amino acid residue 19 to amino acid residue 370, in combination with a pharmaceutically acceptable delivery vehicle, wherein said antibody is an antagonist of said protein, in an amount sufficient to reduce kidney fibrosis in the mammal.

26. (Previously presented) The method of claim 25 wherein the antibody is a monoclonal antibody.

27. (Previously presented) The method of claim 25 wherein the antibody is a humanized antibody.

28. (Previously presented) The method of claim 25 wherein the fibroproliferative disorder of kidney is glomerulonephritis, diabetic nephropathy, or lupus nephritis.

29. (Previously presented) The method of claim 25 wherein the fibroproliferative disorder of kidney is glomerulonephritis.

30. (Previously presented) The method of claim 25 wherein the antibody binds to an epitope of a protein as shown in SEQ ID NO:2 from amino acid residue 258 to amino acid residue 370.

31. (Previously presented) The method of claim 30 wherein the fibroproliferative disorder of kidney is glomerulonephritis, diabetic nephropathy, or lupus nephritis.

32. (Previously presented) The method of claim 30 wherein the fibroproliferative disorder of kidney is glomerulonephritis.